Banook Medical Services SAS

Banook Medical Services SAS, based in France, specializes in providing essential clinical trial services including cardiac safety and electronic Clinical Outcome Assessments, supporting pharmaceutical and biotechnology companies in their research efforts. Founded in 1999 in Nancy, France, Banook Medical Services SAS operates as a global core laboratory that enhances clinical trial quality. The company focuses on clinical trials and has engaged in two significant deals, with its most recent transaction occurring on October 19, 2023. The firm is not noted to have undergone significant changes in its operational strategy since its inception.

Banook offers a comprehensive suite of services focused on clinical trials, specifically targeting areas such as cardiac safety, central imaging, electronic Clinical Outcome Assessments (eCOA/ePRO), and endpoint adjudication. With over 25 years of industry experience, Banook functions as a global core laboratory, providing expertise that spans all phases of clinical trials from Phase I to IV. The company caters to a diverse clientele, including pharmaceutical and biotechnology companies, academic institutions, and healthcare organizations. Banook's services are deployed across key geographical markets including North America, Europe, and Asia-Pacific, ensuring alignment with the unique needs of each study.

In the most recent year, 2020, Banook reported a revenue of USD 914,597 and an EBITDA of USD 345,096. 3, demonstrating its structured revenue model which is based on direct service provision to clients engaged in clinical trials. The company typically partners with pharmaceutical and biotech firms, providing specialized services billed on a project basis. Following the acquisition by Motion Equity Partners in October 2023, Banook Medical Services SAS aims to accelerate its international development, particularly targeting the US market.

The acquisition will support the company in launching new products and expanding its services in broader regions. Specific upcoming products and their release dates have not been disclosed.